AAAAAA

   
Results: 1-3 |
Results: 3
Pharmacokinetic evaluation of N-[2(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography
Authors: Saleem, A Harte, RJ Matthews, JC Osman, S Brady, F Luthra, SK Brown, GD Bleehen, N Conners, T Jones, T Price, PM Aboagye, EO
Citation: A. Saleem et al., Pharmacokinetic evaluation of N-[2(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography, J CL ONCOL, 19(5), 2001, pp. 1421-1429
Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours
Authors: Thomas, HD Lind, MJ Ford, J Bleehen, N Calvert, AH Boddy, AV
Citation: Hd. Thomas et al., Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours, CANC CHEMOT, 45(4), 2000, pp. 284-290
Use of different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation of time to progression: Reanalysis of the MRC BR2 study
Authors: Chataway, J Stenning, S Bleehen, N Grant, R
Citation: J. Chataway et al., Use of different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation of time to progression: Reanalysis of the MRC BR2 study, J NEURO-ONC, 43(1), 1999, pp. 87-92
Risultati: 1-3 |